Tagreed Alkaltham: Preventing the Risk of Transfusion Reactions Before They Occur
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Preventing Transfusion Reactions
How Do We Reduce the Risk Before It Happens?
Engineering Safety in Transfusion Medicine
After discussing recognition and post-transfusion work-up,
a more important question emerges:
How do we reduce the likelihood of a reaction before it ever happens?
In transfusion medicine, safety is not a response.
It is a system.
Prevention Begins Before Issue:
Risk reduction starts long before blood reaches the bedside:
- Accurate patient identification
- Proper antibody screening and history review
- Reviewing previous transfusion reactions
- Selecting special requirements when indicated (irradiated, etc.)
Many severe reactions are preventable at this stage.
Product Integrity Matters:
A strong system protects through:
- Proper storage and temperature monitoring
- Visual inspection before release
- Bacterial risk mitigation strategies
- Clear documentation and traceability
Safety is consistency, not luck.
The Bedside Is the Final Safety Layer:
- Independent identity verification
- Baseline vital signs
- Controlled initial infusion rate
- Early recognition of subtle symptoms
The first minutes matter, but they should not be the only defense.
Governance Makes Prevention Sustainable:
- Reaction audits
- Near-miss reporting
- Trend analysis
- Education feedback loops
Prevention is data-driven.
It is measured.
It is continuously refined.
Transfusion reactions are clinical events.
Prevention is a leadership decision.
Safety in transfusion medicine is not built in crisis
it is engineered long before the first drop flows”
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 16:52Giuseppe Lippi: New Insights Into Antiphospholipid Antibodies and Cardiovascular Thrombosis
-
Mar 13, 2026, 16:51Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
-
Mar 13, 2026, 16:47Sinju Thomas: Combined Red Cell and Plasma Exchange for Severe FES in Sickle Cell Disease
-
Mar 13, 2026, 16:44Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
-
Mar 13, 2026, 16:36Muhammad Bilal: Principles and Clinical Uses of the Coombs Test
-
Mar 13, 2026, 16:27Nikhil Ganjoo: Early Detection of Rare Diseases Through Newborn Genome Sequencing
-
Mar 13, 2026, 16:18Tareq Abadl: Anemia of Inflammation – Hepcidin Regulation of Iron
-
Mar 13, 2026, 16:15New Evidence From the COBRRA Trial in Acute VTE – THANZ
-
Mar 13, 2026, 16:09Wolfgang Miesbach: Brussels Will Be the Perfect Stage for EAHAD 2027